Tuberculosis (TB) is the deadliest infectious disease in most low- and middle-income countries, claiming more than 4,000 lives each day. The unprecedented COVID-19 pandemic has seriously impacted pe...ople with pre-existing health conditions. People with TB are usually more vulnerable to other infections, including the novel coronavirus, due to pre-existing lung damage. They are also at higher risk of developing complications from COVID-19.
more
28 September 2021
Less than half of required funding has been provided globally with dramatic consequences as
hundreds of thousands more die from TB
4 march 2022
What have we learned about the symptoms of Long COVID or Post COVID-19 condition so far? How long does it last, when should you worry..., and what treatments are recommended? WHO’s Dr Janet Diaz explains in Science in 5.
more
20 April 2022. The response to the COVID-19 pandemic continues to adversely affect essential TB services in many countries. A first report of case studies was published in 2021 comprising 23 example...s of innovative interventions implemented by countries to effectively respond to disruptions of TB services caused or exacerbated by the COVID-19 pandemic. This second, consolidated report incorporates new case studies, as well as updates to previously reported case studies
more
11 May 2022
What are WHO's recommendations for COVID-19 vaccines and children? And what does the evidence say so far about the safety of these vaccines in children? And if you live in a country whe...re this vaccination is not available for your kids, how can you keep them safe? WHO’s Dr Soumya Swaminathan explains in Science in 5.
more
The pandemic has emphasized the high risk of avoidable harm to patients, health workers, and the general public, and has identified a range of safety gaps across all core components of health systems at all levels.
The rapid review ‘Implications of the ...">COVID-19 pandemic for patient safety’ explores impacts that the COVID-19 pandemic did have on patient safety in terms of risks and avoidable harm, specifically in terms of diagnostic, treatment and care management related issues as well as highlights the main patterns of these implications within the broader health system context.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
For patients on HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the prong for any sign of mechanical damage, confirm it fits and the filters are in place. Ensure the settings are appropriate and flow is max...imized.
• Check the oxygen source: there is sufficient oxygen available and flowing through the device. If FiO2 > 50% of oxygen is needed, the device must have a blender.
• Check there is no obstruction with secretions: patients with COVID-19 may have very thick secretions which may block small and large airways and cause sudden respiratory deterioration.
more
WHO recommends prompt recognition of progressive acute hypoxaemic respiratory failure when a patient with respiratory distress is failing to respond to standard oxygen therapy and adequate preparation to provide advanced oxygen/ventilatory support.
Hypoxaemic respiratory failure in ARDS commonly re...sults from intrapulmonary ventilation-perfusion mismatch or shunt and usually requires mechanical ventilation.
At any time, if there are urgent or emergent indications for intubation, do not delay.
WHO suggests that hospitalized patients with severe or critical COVID-19 with acute hypoxaemic respiratory failure that do not require emergent intubation be treated with HFNO, or CPAP or NIV (BiPAP) rather than standard oxygen therapy.
more
WHO recommends prompt recognition of progressive acute hypoxaemic respiratory failure when a patient with respiratory distress is failing to respond to standard oxygen therapy and adequate preparation to provide advanced oxygen/ventilatory support.
Hypoxaemic respiratory failure in ARDS commonly ...results from intrapulmonary ventilation-perfusion mismatch or shunt and usually requires mechanical ventilation.
At any time, if there are urgent or emergent indications for intubation, do not delay.
We recommend prompt recognition of progressive acute hypoxaemic respiratory failure when a patient with respiratory distress is failing to respond to standard oxygen therapy and adequate preparation to provide advanced oxygen/ventilatory support.
WHO suggests that patients with severe or critical COVID-19 with acute hypoxaemic respiratory failure that do not require emergent intubation be treated with HFNO, or CPAP or NIV (BiPAP) over standard oxygen therapy.
more
For patients on NIPPV or HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the mask for any sign of mechanical damage, confirm it fits securely without leak (if CPAP/BiPAP) and the filters are in place. Ensur...e the settings are appropriate and flow is maximized.
• Check the oxygen source: there is sufficient oxygen available and flowing through the device. If FiO2 > 50% of oxygen is needed, the ventilator must have a blender.
• Check there is no obstruction with secretions: patients with COVID-19 may have very thick secretions which may block small and large airways and cause sudden respiratory deterioration.
more
This fact sheet highlights the relationship between alcohol consumption and COVID-19. Heavy episodic drinking is considered a health risk for COVID...-19, and alcohol is used by some to cope with difficult emotions that increased during the pandemic.
more
Esta ficha informativa destaca a relação entre o consumo de álcool e a COVID-19. O consumo episódico pesado é considerado um risco à saúde para a C...OVID-19, e o álcool é usado por alguns para lidar com as emoções difíceis que aumentaram durante a pandemia.
more
Esta hoja informativa destaca la relación entre el consumo de alcohol y la COVID-19. El alcohol se utiliza a menudo para la socialización y por algunas personas para hacer frente a las emociones d...ifíciles como la ansiedad, el miedo, la depresión, el aburrimiento y la incertidumbre, todo lo cual aumentó durante la pandemia de COVID-19, con el consiguiente incremento en el consumo de alcohol, especialmente en quienes ya bebían en exceso.
more